Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Copyright policy )Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Dalbavancin is a novel parenteral lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. Dalbavancin is highly active against common Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin has a prolonged half-life that allows for once weekly dosing. Phase III trials have demonstrated non-inferiority compared with vancomycin/linezolid in the treatment of ABSSSIs, including those sustained by MRSA.
Methicillin-Resistant Staphylococcus aureus, Dose-Response Relationship, Drug, Microbial Sensitivity Tests, Skin Diseases, Bacterial, Staphylococcal Infections, Anti-Bacterial Agents, Treatment Outcome, Clinical Trials, Phase III as Topic, Humans, Administration, Intravenous, Teicoplanin, Randomized Controlled Trials as Topic
Methicillin-Resistant Staphylococcus aureus, Dose-Response Relationship, Drug, Microbial Sensitivity Tests, Skin Diseases, Bacterial, Staphylococcal Infections, Anti-Bacterial Agents, Treatment Outcome, Clinical Trials, Phase III as Topic, Humans, Administration, Intravenous, Teicoplanin, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).16 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!